Back to top
more

McKesson (MCK)

(Real Time Quote from BATS)

$595.54 USD

595.54
432,346

+5.55 (0.94%)

Updated Jul 25, 2024 03:54 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 42% (105 out of 250)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Thermo Fisher (TMO) to Offer Wheat & Sesame Allergy Testing

by Zacks Equity Research

Thermo Fisher's (TMO) ImmunoCAP blood tests receive FDA approval for wheat and sesame allergy diagnosis.

Here's Why You Should Buy ShockWave Medical (SWAV) Stock

by Zacks Equity Research

ShockWave Medical (SWAV) continues to benefit from solid R&D efforts and commitment to clinical studies.

Here's Why You Should Hold on to NextGen (NXGN) Stock Now

by Zacks Equity Research

NextGen's (NXGN) solid product portfolio and continued demand for its solutions raise optimism about the stock.

Here's Why You Should Hold on to Catalent (CTLT) Stock Now

by Zacks Equity Research

Catalent's (CTLT) robust facility expansion activities and a slew of strategic deals raise optimism about the stock.

Is Argenx (ARGX) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how argenex SE (ARGX) and McKesson (MCK) have performed compared to their sector so far this year.

Here's Why You Should Retain PerkinElmer (PKI) Stock Now

by Zacks Equity Research

PerkinElmer (PKI) continues to gain momentum from a solid product portfolio and healthy margins. However, forex woes linger.

Here's Why You Should Retain Cooper Companies (COO) Stock Now

by Zacks Equity Research

Cooper Companies (COO) continues to benefit from strength in its business segments. Its acquisitions are likely to boost the top line further.

3 Reasons to Hold QuidelOrtho (QDEL) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about QuidelOrtho (QDEL) owing to its strong product portfolio.

Abiomed's (ABMD) Impella Favored by Latest Study Result

by Zacks Equity Research

Abiomed's (ABMD) Impella-supported high-risk PCI leads to significant improvements in cardiovascular patient outcomes, per latest study.

Zacks.com featured highlights TotalEnergies, ArcBest, Dollar General, McKesson and Archer-Daniels-Midland

by Zacks Equity Research

TotalEnergies, ArcBest, Dollar General, McKesson and Archer-Daniels-Midland have been highlighted in this Screen of The Week article.

West Pharmaceutical's (WST) Latest Investment to Boost Business

by Zacks Equity Research

West Pharmaceutical's (WST) minority investment is expected to aid in meeting patients' continuously evolving needs of ease of use and effective methods of medicine delivery.

Charles River (CRL) Business Hurt by Macro and FX Headwinds

by Zacks Equity Research

In Q2, the impact of foreign currency translation reduces Charles River's (CRL) reported revenue growth by 3.4%.

Sweta Killa headshot

Dividend Growth Investing in Vogue: 5 Stock Picks

by Sweta Killa

Top-ranked dividend stocks like TotalEnergies (TTE), ArcBest (ARCB), Dollar General (DG), McKesson (MCK) and Archer-Daniels-Midland (ADM) are worth adding to your portfolio.

3 Reasons to Retain Ecolab (ECL) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Ecolab (ECL) owing to its solid product portfolio.

Are Investors Undervaluing AmerisourceBergen (ABC) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

McKesson's (MCK) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

McKesson's (MCK) fiscal first-quarter 2023 results benefit from segmental growth.

McKesson (MCK) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

McKesson (MCK) delivered earnings and revenue surprises of 9.79% and 5.14%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Is McKesson (MCK) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how McKesson (MCK) and argenex SE (ARGX) have performed compared to their sector so far this year.

The Zacks Analyst Blog Highlights McKesson, AmerisourceBergen, LHC Group and Glaukos

by Zacks Equity Research

McKesson, AmerisourceBergen, LHC Group and Glaukos are part of Zacks top Analyst Blog.

Indrajit Bandyopadhyay headshot

Medical Device Stocks' Earnings on Aug 3: MCK, ABC & More

by Indrajit Bandyopadhyay

Medical Device players are likely to have benefited from the reopening of economies and several efforts to combat staffing challenges. Let's see how MCK, ABC, LHCG and GKOS fare this time.

McKesson (MCK) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

McKesson's (MCK) fiscal first-quarter results are likely to reflect the solid show by the U.S. Pharmaceutical and Specialty Solutions segment.

McKesson (MCK) Gains But Lags Market: What You Should Know

by Zacks Equity Research

McKesson (MCK) closed the most recent trading day at $340.12, moving +0.15% from the previous trading session.

Analysts Estimate Becton Dickinson (BDX) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Becton Dickinson (BDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Align Technology (ALGN) Q2 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Align Technology (ALGN) delivered earnings and revenue surprises of -5.66% and 0.57%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate McKesson (MCK) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

McKesson (MCK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.